image credit: Freepik

With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease

July 1, 2024

Like many of its cell therapy peers, Artiva reshuffled its strategy hoping to ride a recent wave of investor interest in autoimmune disease research.

The company is one of a number of biotechs to emerge in recent years to develop so-called allogeneic or “off-the-shelf” cell therapies, which are thought of as convenient, easier-to-manufacture alternatives to the personalized CAR-T treatments used on a handful of blood cancers. Unlike those therapies, Artiva’s are harvested from donor cells. They’re also made from NK cells, which have different characteristics than the immune cells involved in CAR-T therapy.

Read More on Biopharma Dive